Cargando…
Virally programmed extracellular vesicles sensitize cancer cells to oncolytic virus and small molecule therapy
Recent advances in cancer therapeutics clearly demonstrate the need for innovative multiplex therapies that attack the tumour on multiple fronts. Oncolytic or “cancer-killing” viruses (OVs) represent up-and-coming multi-mechanistic immunotherapeutic drugs for the treatment of cancer. In this study,...
Ejemplares similares
-
A T cell-targeted multi-antigen vaccine generates robust cellular and humoral immunity against SARS-CoV-2 infection
por: Boulton, Stephen, et al.
Publicado: (2023) -
A High-Throughput NanoBiT-Based Serological Assay Detects SARS-CoV-2 Seroconversion
por: Azad, Taha, et al.
Publicado: (2021) -
Hippo Signaling Pathway as a Central Mediator of Receptors Tyrosine Kinases (RTKs) in Tumorigenesis
por: Azad, Taha, et al.
Publicado: (2020) -
Single-dose replicating poxvirus vector-based RBD vaccine drives robust humoral and T cell immune response against SARS-CoV-2 infection
por: Boulton, Stephen, et al.
Publicado: (2022) -
SARS-CoV-2 S1 NanoBiT: A nanoluciferase complementation-based biosensor to rapidly probe SARS-CoV-2 receptor recognition
por: Azad, Taha, et al.
Publicado: (2021)